Chicago—Evidence for assessing the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents for treating corneal and ocular surface disease is accumulating. However, there is clearly a need for more research to define if, when, and how this therapy should be used, said Anat Galor, MD.
Dr. Galor reviewed the available literature on anti-VEGF agents for treatment of corneal neovascularization and in the management of pterygium at Cornea Subspecialty Day here during the annual meeting of the American Academy of Ophthalmology.
Findings of studies to date indicate that anti-VEGF treatment—either topically or as a subconjunctival injection—appears to have a positive effect on corneal and conjunctival blood vessels, she said.
However, the ability to change the course of disease is unclear and there seem to be potential safety concerns, particularly with topical administration, said Dr. Galor, associate professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.